Graffinity and Mutabilis announce second research collaboration
Drug Discovery Collaboration to Focus on Infectious Disease Targets
Under the terms of the agreement Mutabilis will provide Graffinity with target proteins identified by Mutabilis. Graffinity will apply its proprietary RAISE® (Rapid Affinity Instructed Structure Evolution) Technology and drug-fragment chemical microarrays to identify and evolve small molecule hit structures with a focus on compounds with novel modes of action. Graffinity will receive a technology access fee and a milestone payment upon conclusion of the collaboration.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.